Skip to main content
. Author manuscript; available in PMC: 2008 Dec 8.
Published in final edited form as: J Med Chem. 2005 Dec 29;48(26):8103–8107. doi: 10.1021/jm050726b

Table 1.

Potency of adenosine derivatives at human A1, A2A, and A3ARs and the rat A3AR a and maximal agonist effects at human A3ARs expressed in CHO cells.a

graphic file with name nihms64827f4.jpg
No. N6-R′ C2-R Ki (hA1AR) nMa Ki (hA2AAR) nMa Ki (hA3AR) nMa % Activation (hA3AR)b at 10 μM Ki (rA3AR)
1c CP H 34.1 ± 6.1 6420 ± 630 13.1 ± 5.1 93 ± 7 10.2 ± 2.1
2c CP Cl 18.3 ± 6.3g 3250 ± 300 3.7 ± 0.9 101 ± 10 5.8 ± 1.6
3c NB Cl 190 ± 37 >10,000 14.6 ± 3.2 92 ± 6 9.6 ± 2.7
4d CP H 0.45±0.04b 462 240±36 72±12 97±4
5d CP Cl 0.83e 2270e 38 ± 6 0 237±71f
6d NB H 0.48±0.01 >10,000 229±76 112±25 103±1
a

All AR experiments were performed using adherent CHO cells stably transfected with cDNA encoding the human or rat ARs. Percent activation of the human A3AR was determined at 10 μM. Binding at human A1 and A2AARs in this study was carried out as described in Methods using [3H]R-PIA or [3H]CGS 21680 as a radioligand. Values from the present study are expressed as mean ± s.e.m., n = 3–5.

b

Percent activity at 10 μM, relative to 10 μM Cl-IB-MECA (A3).

c

1, MRS3706; 2, MRS3630; 3, MRS3638.

d

Data from Gao et al., unless noted.22,23

e

Data from Klotz et al.28

f

Data from van Galen et al.29

g

Ki at rat A1 AR is 17.4 ± 2.7 nM.

ND not determined. CP, cyclopentyl; NB, 7-norbornyl.